Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies

In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Med (New York, N.Y. : Online) N.Y. : Online), 2024-06, Vol.5 (6), p.487-489
Hauptverfasser:	How, Jeffrey A., Jazaeri, Amir A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Chemoradiotherapy - methods Female Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Randomized Controlled Trials as Topic Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival. In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
ISSN:	2666-6340 2666-6340
DOI:	10.1016/j.medj.2024.05.001